FY2024 Earnings Estimate for DTIL Issued By HC Wainwright

Posted by MarketBeat News on Nov 9th, 2024

Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) – Stock analysts at HC Wainwright reduced their FY2024 earnings estimates for Precision BioSciences in a research note issued on Tuesday, November 5th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($1.23) per share for the year, down from their previous estimate of $0.82. HC Wainwright currently has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is $0.82 per share. HC Wainwright also issued estimates for Precision BioSciences’ Q4 2024 earnings at ($0.42) EPS, Q1 2025 earnings at ($0.38) EPS and FY2025 earnings at ($1.05) EPS.

Precision BioSciences Trading Down 0.5 %

NASDAQ DTIL opened at $8.38 on Thursday. The company has a market cap of $60.59 million, a price-to-earnings ratio of 139.69 and a beta of 1.71. The company has a 50 day moving average of $9.22 and a 200-day moving average of $10.03. Precision BioSciences has a 1-year low of $7.97 and a 1-year high of $19.43.

Institutional Trading of Precision BioSciences

Want More Great Investing Ideas?

A hedge fund recently bought a new stake in Precision BioSciences stock. Janus Henderson Group PLC purchased a new stake in Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 573,052 shares of the company’s stock, valued at approximately $7,739,000. Janus Henderson Group PLC owned approximately 8.29% of Precision BioSciences as of its most recent SEC filing. 37.99% of the stock is currently owned by hedge funds and other institutional investors.

About Precision BioSciences

(Get Free Report)

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.